Macquarie Group
INDP icon

Macquarie Group’s Indaptus Therapeutics INDP Stock Holding History

Macquarie Group’s Portfolio INDP Stock Details INDP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1
Closed -$8K – 2256
2017
Q4 		$8K Buy
+1
New +$15.5K ﹤0.01% 2307

Other funds holding INDP

ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return

Macquarie Group's INDP Position: Q1 2018 in Review

Macquarie Group sold out of Indaptus Therapeutics (INDP) in Q1 2018, closing a stake of 1 share — an estimated $8K sold.

Macquarie Group first reported a position in INDP in Q4 2017 and held it in 1 quarter. The position peaked at $8K in Q4 2017. 23 funds tracked by Wall St. Rank hold INDP as of Q1 2018.

  • Macquarie Group reported no remaining Indaptus Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Macquarie Group sold 1 Indaptus Therapeutics share in Q1 2018, an estimated $8K.
  • Macquarie Group first reported a position in Indaptus Therapeutics in Q4 2017 and held it in 1 quarter.
  • Macquarie Group's Indaptus Therapeutics position peaked at $8K in Q4 2017.
  • 23 funds tracked by Wall St. Rank held Indaptus Therapeutics as of Q1 2018.

Based on Macquarie Group's 13F filing for Q1 2018, filed 11 May 2018.